Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors
MADISON, Wisc.–(BUSINESS WIRE)–Invenra’s collaboration partner, Exelixis, Inc. (NASDAQ: NASDAQ:) has announced the initiation of the...